Allogenic iPS cell derived induced nephron progenitor cells - Bios/Jikei University/Sumitomo pharma
Alternative Names: Allo iPS cell derived induced nephron progenitor cells -Sumitomo pharma; Allogenic iPS cell derived induced nephron progenitor cells - Jikei University/Sumitomo pharma/Bios; Allogenic iPS cell derived induced nephron progenitor cells -Sumitomo pharma/Bios/Jikei UniversityLatest Information Update: 13 Sep 2022
At a glance
- Originator Bios; Sumitomo Pharma; The Jikei University School of Medicine
- Developer Sumitomo Pharma
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal failure
Most Recent Events
- 11 Aug 2022 Preclinical trials in Renal failure in Japan (Parenteral)
- 05 Apr 2019 Bios, Meiji University, PorMedTec, Sumitomo Pharma and The Jikei University School of Medicine enters into R&D agreement for the development of Auto/Allo iPS cellbased induced nephron progenitor cells
- 05 Apr 2019 Early research in Renal failure in Japan (Parenteral)